GLENMARK PHARMA: Q3 CONS NET PROFIT 4B RUPEES VS 3.5B (YOY); EST 6.3B || Q3 REVENUE 39B RUPEES VS 33B (YOY)

 30 Jan 2026 08:13 PM

GLENMARK PHARMA: Q3 CONS NET PROFIT 4B RUPEES VS 3.5B (YOY); EST 6.3B || Q3 REVENUE 39B RUPEES VS 33B (YOY)

GLENMARK PHARMA: Q3 EBITDA 9B RUPEES VS 6B (YOY) || Q3 EBITDA MARGIN 23.19% VS 18.18% (YOY)

 30 Jan 2026 08:14 PM

GLENMARK PHARMA: Q3 EBITDA 9B RUPEES VS 6B (YOY) || Q3 EBITDA MARGIN 23.19% VS 18.18% (YOY)

GLENMARK PHARMA: CO HAS EXCEPTIONAL ITEM OF 1.84B RUPEES || Q3 PBT 7.2B RUPEES VS 4.6B (YOY)

 30 Jan 2026 08:15 PM

GLENMARK PHARMA: CO HAS EXCEPTIONAL ITEM OF 1.84B RUPEES || Q3 PBT 7.2B RUPEES VS 4.6B (YOY)

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces New Epinephrine Injection USP, 30 MG/30 ML (1 MG/ML) Multiple-Dose Vial

 23 Dec 2025 09:04 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces New Epinephrine Injection USP, 30 MG/30 ML (1 MG/ML) Multiple-Dose Vial

Glenmark Pharma: Co Signs Exclusive Deal With Hansoh Pharma For Aumolertinib Rights, Totaling Over $1 Billion Payment

 16 Dec 2025 03:47 PM

Glenmark Pharma: Co Signs Exclusive Deal With Hansoh Pharma For Aumolertinib Rights, Totaling Over $1 Billion Payment

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Set To Release Leucovorin Calcium For Injection USP, Starting December 2025.

 11 Dec 2025 08:45 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Set To Release Leucovorin Calcium For Injection USP, Starting December 2025.

Glenmark Pharmaceuticals: U.S. FDA Finishes Inspection At Co's Chhatrapati Sambhajinagar Facility With No Issues Found.

 01 Dec 2025 09:04 AM

Glenmark Pharmaceuticals: U.S. FDA Finishes Inspection At Co's Chhatrapati Sambhajinagar Facility With No Issues Found.

Glenmark Pharmaceuticals: Gets VAI Status From U.S. FDA For Monroe Facility, Resuming Commercial Manufacturing

 27 Nov 2025 10:16 AM

Glenmark Pharmaceuticals: Gets VAI Status From U.S. FDA For Monroe Facility, Resuming Commercial Manufacturing

Glenmark Pharmaceuticals: Introduces First Nebulized Triple Treatment For COPD That Combines Glycopyrrolate, Formoterol, And Budesonide To Enhance Lung Function And Control Symptoms

 25 Nov 2025 09:04 AM

Glenmark Pharmaceuticals: Introduces First Nebulized Triple Treatment For COPD That Combines Glycopyrrolate, Formoterol, And Budesonide To Enhance Lung Function And Control Symptoms

Glenmark Pharma: HSBC on Glenmark Pharma Buy, target price cut to Rs 2110

 19 Nov 2025 09:04 AM

Glenmark Pharma: HSBC on Glenmark Pharma Buy, target price cut to Rs 2110

Glenmark Pharmaceuticals: Gets Approval To Market Winlevi® Cream In 15 European Countries For Treating Acne In Adults And Teens.

 18 Nov 2025 02:41 PM

Glenmark Pharmaceuticals: Gets Approval To Market Winlevi® Cream In 15 European Countries For Treating Acne In Adults And Teens.

Glenmark Pharma: Aims For 12-15% Revenue Growth With Initial EBITDA Margins Of 23%, Planning To Reach 25% Plus Later. They Target Return Ratios Of 25-30% ROCE And 20-25% ROE. The IGI Subsidiary Plans Annual Spending Of $70-75 Million

 18 Nov 2025 09:02 AM

Glenmark Pharma: Aims For 12-15% Revenue Growth With Initial EBITDA Margins Of 23%, Planning To Reach 25% Plus Later. They Target Return Ratios Of 25-30% ROCE And 20-25% ROE. The IGI Subsidiary Plans Annual Spending Of $70-75 Million

Glenmark Pharma: Sets Quarterly Revenue Goals Of ₹1,150-1,200 Crores From Q3 FY26 And Over ₹4,800 Crores For FY27, Targeting Total Revenue Of ₹17,000-18,000 Crores For FY27.

 18 Nov 2025 08:54 AM

Glenmark Pharma: Sets Quarterly Revenue Goals Of ₹1,150-1,200 Crores From Q3 FY26 And Over ₹4,800 Crores For FY27, Targeting Total Revenue Of ₹17,000-18,000 Crores For FY27.

Glenmark Pharma: Co Management Says That It Aims To Grow Revenues 15% Yearly Going Forward || Co Says That They Aim On Their EBITDA Margin Moving Up To 25% Going Forward And The Co Is Aiming To Be Gross Debt Free In The Coming Time - Concall Updates

 17 Nov 2025 09:41 AM

Glenmark Pharma: Co Management Says That It Aims To Grow Revenues 15% Yearly Going Forward || Co Says That They Aim On Their EBITDA Margin Moving Up To 25% Going Forward And The Co Is Aiming To Be Gross Debt Free In The Coming Time - Concall Updates

Glenmark Pharma: Co Expects Sales in India to Recover from Q3, Aiming for ₹1150-1200 Crore From Q3 This Year and ₹4800 Crore for the Next Year -Concall Updates

 17 Nov 2025 09:16 AM

Glenmark Pharma: Co Expects Sales in India to Recover from Q3, Aiming for ₹1150-1200 Crore From Q3 This Year and ₹4800 Crore for the Next Year -Concall Updates

Glenmark Pharma: Co Management Says That In FY26 The Co Will Surely Be A Gross Debt Zero Co - Concall Updates

 17 Nov 2025 09:24 AM

Glenmark Pharma: Co Management Says That In FY26 The Co Will Surely Be A Gross Debt Zero Co - Concall Updates

Glenmark Pharma: Co Is Targeting A Revenue Between 17,000 And 18,000 Crores By The End Of FY27 - Concall Updates

 17 Nov 2025 09:07 AM

Glenmark Pharma: Co Is Targeting A Revenue Between 17,000 And 18,000 Crores By The End Of FY27 - Concall Updates

Glenmark Pharmaceuticals: Co Guides For Re-Rated Profitability Post AbbVie Biotech Deal; Consolidated EBITDA Margin To Rise To ~23 % From H2 FY26; US $ 1.9 Bn AbbVie Partnership Funds R&D And Debt Reduction; Focus On High-Growth Therapies (Respiratory, Oncology, Dermatology); Expanding CRDMO Capabilities And Global Commercialization In Emerging Markets To Drive Sustained Growth

 14 Nov 2025 09:31 PM

Glenmark Pharmaceuticals: Co Guides For Re-Rated Profitability Post AbbVie Biotech Deal; Consolidated EBITDA Margin To Rise To ~23 % From H2 FY26; US $ 1.9 Bn AbbVie Partnership Funds R&D And Debt Reduction; Focus On High-Growth Therapies (Respiratory, Oncology, Dermatology); Expanding CRDMO Capabilities And Global Commercialization In Emerging Markets To Drive Sustained Growth

GLENMARK PHARMA: Q2 CONS NET PROFIT 6.1B RUPEES VS 3.54B (YOY) || Q2 REVENUE 60.5B RUPEES VS 34B (YOY)

 14 Nov 2025 06:32 PM

GLENMARK PHARMA: Q2 CONS NET PROFIT 6.1B RUPEES VS 3.54B (YOY) || Q2 REVENUE 60.5B RUPEES VS 34B (YOY)

GLENMARK PHARMA: Q2 EBITDA 23.6B RUPEES VS 6.1B (YOY) || Q2 EBITDA MARGIN 39.03% VS 17.88% (YOY)

 14 Nov 2025 06:34 PM

GLENMARK PHARMA: Q2 EBITDA 23.6B RUPEES VS 6.1B (YOY) || Q2 EBITDA MARGIN 39.03% VS 17.88% (YOY)